Navigation Links
Genmab Announces Year End 2007 Financial Results
Date:3/31/2008

venues in 2008, we are projecting an operating loss of DKK 900 to 1,000 million compared to the DKK 437 million reported for 2007. Under the conditions described above, the net loss for 2008 is expected to be in the range of DKK 800 to 900 million compared to the net loss of DKK 383 million reported for 2007.

As of December 31, 2007, Genmab had cash, cash equivalents and short-term marketable securities of DKK 3.7 billion (approximately USD 728 million). We expect the 2008 cash burn to consist of USD 240 million (approximately DKK 1.2 billion) paid for the acquisition of the manufacturing facility, operational expenses of approximately DKK 750-800 million (approximately USD 148-158 million) and approximately DKK 40-50 million (approximately USD 8-10 million) in other capital expenditures. We expect to spend over 90% of our 2008 budget on research and development, including the operation of our manufacturing facility and less than 10% on general and administrative expenses. Of the research and development costs, we expect to spend approximately DKK 500 million (approximately USD 98 million) on development for the ofatumumab program.

Total projected revenues for 2008 are expected to be approximately DKK 1.0 billion (approximately USD 197 million), an increase of approximately DKK 470 million (approximately USD 93 million) over 2007 revenues, which were 530 million (approximately USD 104 million). Net financial income is expected to be approximately DKK 70-75 million (approximately USD 14-15 million). Thus, including the manufacturing acquisition and operational expenses, we are projecting a 2008 year end cash position of DKK 1.7 to 1.8 billion (approximately USD 335 to 355 million).

The estimates above are subject to possible change primarily due to the timing and variation of development activities, related income and costs and fluctuating exchange rates. Our projected 2008 revenues consist primarily of milestone payments, for which we cannot alw
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Genmab Announces 2007 First Half Year Results
2. Genmab Announces Encouraging Preclinical Data for ofatumumab
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Genmab Announces Asset Exchange Agreement
5. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
6. Genmab A/S - Company Announcement
7. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Announces Results for the First Nine Months of 2007
10. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
11. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Dec. 16 /PRNewswire/ -- ... life sciences industry and an active venture capital ... Indiana State Teachers Retirement Fund, Indiana University, Purdue ... Fairbanks Foundation, and Credit Suisse today announced the ... venture capital fund of funds. ,, Organized through ...
(Date:12/16/2009)... Sequenom, Inc. (Nasdaq: SQNM ), today announced ... David Pendarvis to its board of directors. ... F. Buechler, Ph.D., was president, chief scientific officer ... 1994, Dr. Buechler was Biosite,s director of chemistry. ... senior research scientist for the diagnostics research and ...
(Date:12/16/2009)... Eppendorf has initiated an,import ban ... systems for,infringement of European patent EP 1 ... and/or the quantification of a target compound". ... of the respective products into any country ... to confiscate any,violating products. , ...
(Date:12/15/2009)... 15 Epeius Biotechnologies Corporation, an emerging ... gained international validation of the cutting-edge science behind ... scientists around the world rediscovered the Cyclin ... of cancer pathogenesis and disease progression, and thus ... at the NIH National Cancer Institute investigating the ...
Breaking Biology Technology:Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 2Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 3Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 4Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 5Sequenom Appoints Two New Board Members 2Sequenom Appoints Two New Board Members 3Eppendorf Successfully Initiates Import ban Against Nanosphere, Inc. for the Countries of the European Union 2Scientists Rediscover Gene Target for Cancer Therapy 2Scientists Rediscover Gene Target for Cancer Therapy 3
... PHLC) ("Phlo") announced today that one of its affiliates,(the ... beverage,product, AQISS(TM), as part of a roll out of ... Manhattan, Brooklyn, Queens, the,Bronx, and Long Island., AQISS(TM) ... of which are as,follows:, , -- Financial ...
... (Amex: ETC ) ("ETC" or the "Company") ... BARA-MED(R) XD Monoplace,Hyperbaric Chambers by Comprehensive Healthcare Solutions, ... Solutions a growing company,who focuses solely on initiating ... ETC prides itself on being the manufacturer ...
... Cell Therapeutics, Inc.,(CTI) (Nasdaq and MTAX: CTIC) management ... 8:30 am EST to discuss update on Zevalin asset,purchase, ... Conference Call Numbers Thursday, December 27 8:30 ... 303-262-2130, Webcast available at http://www.cticseattle.com ...
Other Biology Technology:Phlo Affiliate Begins Roll Out to Metropolitan New York City Account Base 2Environmental Tectonics Corporation Announces Sale of Monoplace Hyperbaric Chambers 2Environmental Tectonics Corporation Announces Sale of Monoplace Hyperbaric Chambers 3
(Date:12/15/2009)... -- The 2009 Frost & Sullivan European ... to Sagem Securite (Safran Group) for its ... recognises the company,s expertise in advanced biometric ... novel, value-added products to end users. ... "Sagem Securite has been involved in delivering ...
(Date:12/15/2009)... has just signed an agreement with the British Society ... affiliation with the journal Biogerontology for an ... appoint one member of the Biogerontology editorial ... annually. Springer will sponsor the society and provide ... on www.springerlink.com . , Biogerontology ...
(Date:12/15/2009)... and Ghent University in Flanders, Belgium have found an ... major cause of death in intensive care units. By ... mice with septic shock, researchers Anje Cauwels and Peter ... damage, while their chances of survival increased significantly. That,s ... that nitric oxide is responsible for the potentially lethal ...
Breaking Biology News(10 mins):Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 2Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 3Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 4Septic shock: Nitric oxide beneficial after all 2Study finds racial disparities exist in radiation therapy rates for early stage breast cancer 63199 1Study finds racial disparities exist in radiation therapy rates for early stage breast cancer 63199 2Study finds racial disparities exist in radiation therapy rates for early stage breast cancer 63199 3Gas improves blood flow and organ status during minimally invasive surgery 11132 1Gas improves blood flow and organ status during minimally invasive surgery 11132 2The Queen and I 63196 1
... over decades may add a few years to a human ... 125 and beyond, as many have speculated, evolutionary biologists report. ... remain super-skinny is not going to have a big payoff ... John Phelan. "I once heard someone say caloric restriction may ...
... vast and uniform. But beneath the surface, tiny animals ... ocean currents. The very survival of many zooplankton predators--from ... depend on their success at finding those patches. , ... these patches form when the zooplankton swim against the ...
... at The Scripps Research Institute are reporting that mice created ... LPA receptor have fertility problems, which suggests that these receptors ... issue of the journal Nature, the scientists detail how mice ... of cells in a mouse's womb, have fertility problems. These ...
Other Biology News:Caloric restriction won't dramatically extend life span in humans: UCLA research 2Caloric restriction won't dramatically extend life span in humans: UCLA research 3Researchers use 3-D imaging system to unveil swimming behavior of microscopic plankton 2Researchers use 3-D imaging system to unveil swimming behavior of microscopic plankton 3Scripps research scientists identify infertility molecule 2Scripps research scientists identify infertility molecule 3Scripps research scientists identify infertility molecule 4Scripps research scientists identify infertility molecule 5
... monoclonal [6331] to Salmonella typhimurium The genus ... The genus is composed of Gram-negative bacilli that ... major antigens; the "H" or flagellar antigen (phase ... (part of the LPS moiety) and the "Vi" ...
... system from Molecular Devices provides precise dispensing ... The system handles a variety of plate ... and 1536-welland is the first to handle ... optimized to dispense from four different channels ...
... With 36 mg/L sodium pyruvate, 50 mg/L ... mg/L glucose, calcium chloride, and magnesium chloride. ... (BSS) in tissue culture is generally attributed ... 1885, Sydney Ringer developed a solution of ...
This free-standing laminar flow hood provides a horizontal flow of HEPA-filtered air to create a clean processing area. Air return slots along the front and side edges of the work area enhance system...
Biology Products: